Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
Vor Biopharma VOR, a clinical-stage company, announced dosing the first patient in its phase I/II study of VCAR33ALLO for the treatment of relapsed/refractory acute myeloid leukemia (AML). VCAR33ALL...